Two Sigma Investments
SLN

Two Sigma Investments’s Silence Therapeutics SLN Stock Holding History

Two Sigma Investments’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85.4K Sell
16,203
-23,141
-59% -$127K ﹤0.01% 4406
2025
Q4 		$239K Sell
39,344
-23,903
-38% -$153K ﹤0.01% 3692
2025
Q3 		$328K Buy
63,247
+3,935
+7% +$21.9K ﹤0.01% 3179
2025
Q2 		$344K Sell
59,312
-16,696
-22% -$71.6K ﹤0.01% 2740
2025
Q1 		$214K Sell
76,008
-66,044
-46% -$322K ﹤0.01% 2829
2024
Q4 		$977K Sell
142,052
-27,340
-16% -$353K ﹤0.01% 2195
2024
Q3 		$3.08M Buy
169,392
+70,285
+71% +$1.31M 0.01% 1376
2024
Q2 		$1.88M Sell
99,107
-8,105
-8% -$172K ﹤0.01% 1588
2024
Q1 		$2.32M Buy
+107,212
New +$2.33M 0.01% 1372

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Two Sigma Investments's SLN Position: Q1 2026 in Review

Two Sigma Investments reduced its Silence Therapeutics (SLN) stake by 59% in Q1 2026, selling an estimated $127K and leaving 16,203 shares worth $85.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4406.

Two Sigma Investments first reported a position in SLN in Q1 2024 and has held it in 9 quarters since. The position peaked at $3.08M in Q3 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Two Sigma Investments held 16,203 shares of Silence Therapeutics worth $85.4K as of Q1 2026.
  • Two Sigma Investments sold 23,141 Silence Therapeutics shares in Q1 2026, an estimated $127K.
  • Silence Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #4406 holding.
  • Two Sigma Investments first reported a position in Silence Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Two Sigma Investments's Silence Therapeutics position peaked at $3.08M in Q3 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.